Purity vs Identity: Why a Peptide Lot Needs Both HPLC and Mass Spectrometry

High-performance liquid chromatography pushes a sample through a packed column under pressure so components separate by their affinity for the stationary phase. For peptides the standard configuration is reverse phase with ultraviolet detection near 214 nm. The output is a chromatogram, and purity is the fraction of total integrated peak area belonging to the target.

The limits follow directly from that definition. HPLC only sees what the detector responds to, so a non-absorbing contaminant such as inorganic salt or residual water is invisible to a UV area-percent calculation. Two species that co-elute are counted as one peak. And chromatography assigns no identity: the main peak is the target only because a reference standard or an orthogonal method says so.

Mass spectrometry ionizes the sample and measures mass-to-charge ratios. Because the mass calculated from an amino acid sequence is specific, agreement between calculated and observed mass within instrument tolerance is strong evidence of identity, and characteristic offsets identify specific modifications such as oxidation, dehydration, deletion of a residue or dimerization.

Quantitation is the weakness. Ionization efficiency varies by molecule, suppression effects change signal in mixtures, and a species that ionizes poorly can be abundant yet nearly absent from the spectrum. Relative peak intensity in a mass spectrum is therefore not a purity percentage.

Used together the two are complementary: chromatography establishes how much of the sample is one species, spectrometry establishes which species that is. Liquid chromatography coupled to mass spectrometry (LC-MS) closes the remaining gap by assigning a mass to each resolved peak, which turns an anonymous impurity peak into an identified related substance.

In standards language this is the concept of specificity: an analytical procedure must be shown to measure the target unequivocally in the presence of everything else that may be present. ICH Q2(R2) and FDA method validation guidance describe the demonstrations expected of a procedure before its numbers can be relied upon.

When comparing lots or suppliers, compare methods first. Column chemistry, gradient length, modifier, flow rate and detection wavelength all move the reported number, and a purity value quoted without its method is not a comparable figure. On the mass side, check whether the reported mass is monoisotopic or average and which charge state and adduct the instrument observed.

A lot record that publishes the chromatogram image, the method conditions, the calculated and observed masses and the issuing laboratory can be audited. One that publishes a single percentage cannot. All products referenced on this site are supplied for in-vitro laboratory research use only. They are not drugs, foods, cosmetics or medical devices, and they are not for human or veterinary consumption or administration.